Strengthening the Financial Base to Support Upfront Investments
First written in FY2024. 5 of 6 entries say "Worsened", first in FY2025-H1. Latest entry: 2026-08-14.
PRISM BioLab moved to the "Worse" side of this theme in 2025, 1 year before the typical company in this theme (2026).
2 other companies' latest entry also says "Worsened".
- FY2025WorsenedAnnual report
「While pursuing ongoing monetization, cash and deposits at the end of the fiscal year stood at ¥2,915,572 thousand. Alongside further business expansion, cost reductions and strengthening of the financial base are also required.」
Cash and cash equivalents decreased by ¥1,476,449 thousand from the end of the previous fiscal year to ¥2,915,572 thousand. The need to strengthen the financial base remains. - FY2025-H1WorsenedAnnual report
「During the interim accounting period, cash and cash equivalents (hereinafter, "funds") decreased by ¥655,303 thousand from the end of the previous fiscal year to ¥3,736,718 thousand.」
Cash and cash equivalents supporting upfront investment decreased by ¥655,303 thousand from the end of the previous fiscal year. - FY2024First statedAnnual report
「While pursuing ongoing monetization, cash and deposits at the end of the fiscal year stood at ¥4,392,022 thousand. Alongside further business expansion, cost reductions and strengthening of the financial base are also required.」
Given that research and development investment and overhead expenses exceed revenue from the collaborative development business, we are also considering diversifying our sources of funding.